Denali Therapeutics (DNLI) Debt Ratio (2022)
Denali Therapeutics (DNLI) reported Debt Ratio of 0.0 for Q4 2022, up 155.64% quarter-over-quarter from 0.0 in Q3 2022.
Denali Therapeutics (DNLI) Debt Ratio (2022) Analysis & Trends
Denali Therapeutics (DNLI) has 1 years of Debt Ratio data on file, last reported at 0.0 in Q4 2022.
- Debt Ratio for Q4 2022 came in at 0.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was 0.0 (changed N/A YoY), and the FY2022 annual result was 0.0, changed N/A from the prior year.
- Debt Ratio improved to 0.0 in Q4 2022 per DNLI's latest filing, from 0.0 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.0 in Q4 2022 and troughed at 0.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.18 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |